2026-09-10 · Fuente：Unite AI
Unite AI's interview series profiles Owkin co-founder and CEO Thomas Clozel, M.D., whose clinical background and leadership since 2016 have anchored the AI biotech's fundraising and pharmaceutical partnerships.
Thomas Clozel, M.D., co-founder and chief executive of AI biotech Owkin, is the latest figure to feature in Unite AI's executive interview series, in a conversation that traces the company's trajectory from its 2016 founding to its current standing in the healthcare technology landscape. Owkin, which applies artificial intelligence to biotechnology with the stated aim of transforming healthcare, has grown under Clozel's continuous leadership since its inception.
Clozel's path to the top of an AI company runs through medicine rather than engineering. A clinician by training with a background in clinical research, he previously served as Assistant Professor of Clinical Onco-Hematology at Hôpital Henri. That clinical grounding has shaped his stewardship of Owkin, positioning him to bridge the worlds of hospital-grade research and computational approaches to disease.
The company's record under his tenure rests on two headline achievements flagged in the profile: raising substantial funding and forming strategic partnerships with major pharmaceutical companies. Both are consequential markers for an AI biotech firm, where capital intensity and pharmaceutical validation often determine whether computational platforms move from research promise to commercial relevance. Because Clozel has led Owkin since its 2016 inception, the company has maintained a rare continuity of leadership across its entire lifespan.
For an audience tracking where AI capability and capital are flowing, the profile is a reminder that demand for artificial intelligence extends well beyond chips, models and data centers into life sciences. As Unite AI's interview series continues to spotlight founders working at the intersection of AI and specialized industries, Clozel's account of Owkin's rise offers a case study in how clinical expertise, sustained fundraising and pharmaceutical alliances combine to commercialize AI in healthcare.
Etiquetas: Owkin · Thomas Clozel · AI Biotech · Healthcare AI
萬安算交所 AIXX · AIXX · Exchange verificado · Ir al mercado